摘要
Abstract
Objective:To explore the effects of Evolocumab combined with Rosuvastatin on blood lipid levels and inflammatory reaction in patients with acute coronary syndrome(ACS).Method:The clinical data of 136 patients with ACS admitted to the First People's Hospital of Dongcheng District,Beijing from January 2022 to April 2023 were retrospectively collected.They were divided into control group(n=101,treated with Rosuvastatin)and observation group(n=35,treated with Evolocumab combined with Rosuvastatin)according to different treatment regiments.Two groups were treated continuously for 1 month.The levels of blood lipids[total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and hypersensitive C reactive protein(hs-CRP)]and the occurrence of adverse reactions were compared between two groups.Result:After treatment,TC,TG and LDL-C were decreased and HDL-C was increased in both groups,and those in the observation group were better than those in the control group,the differences were statistically significant(P<0.05).After treatment,IL-6,TNF-α and hs-CRP in both groups were decreased,and those in observation group were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Evolocumab combined with Rosuvastatin can effectively reduce the levels of TC,TG,LDL-C and inflammatory factors in patients with ACS,and increase the level of HDL-C without increasing adverse reactions.关键词
依洛尤单抗/瑞舒伐他汀/急性冠脉综合征/炎症因子Key words
Evolocumab/Rosuvastatin/Acute coronary syndrome/Inflammatory factors
